Ptc Therapeutics (PTCT) Share-based Compensation (2012 - 2026)

Ptc Therapeutics' Share-based Compensation history runs 15 years deep, the most recent figure standing at $206.8 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 1015.25% year-over-year to $206.8 million; the TTM figure through Jun 2026 stood at $206.8 million (up 180.99% YoY), while the FY2025 annual figure was $129.8 million, up 31.11% from the prior year.
• Share-based Compensation for Q2 2026 stood at $206.8 million, down from $231.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $231.7 million in Q1 2026, with the low at $17.2 million in Q4 2024.
• The 5-year median for Share-based Compensation is $26.6 million (2022), against an average of $46.1 million.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation sank 36.22% in 2024, then surged 1182.95% in 2026.
• Ptc Therapeutics' Share-based Compensation stood at $27.3 million in 2022, then dropped by 1.47% to $26.9 million in 2023, then sank by 36.01% to $17.2 million in 2024, then increased by 7.42% to $18.5 million in 2025, then jumped by 1016.75% to $206.8 million in 2026.
• Business Quant data shows PTCT's Share-based Compensation at $206.8 million in Q2 2026, $231.7 million in Q1 2026, and $18.5 million in Q4 2025.